Monoclonal antibodies (mAbs) are widely used in many fields due to their high specificity and ability to recognize a broad range of antigens. IL-17A can induce a rapid inflammatory response both alone and synergistically with other proinflammatory cytokines. Accumulating evidence suggests that therapeutic intervention of IL-17A signaling offers an attractive treatment option for autoimmune diseases and cancer. Here, we present a combinatorial approach for optimizing the affinity and thermostability of a novel anti-hIL-17A antibody. From a large naïve phage-displayed library, we isolated the anti-IL-17A mAb 7H9 that can neutralize the effects of recombinant human IL-17A. However, the modest neutralization potency and poor thermostability limit its therapeutic applications. In vitro affinity optimization was then used to generate 8D3 by using yeast-displayed random mutagenesis libraries. This resulted in four key amino acid changes and provided an approximately 15-fold potency increase in a cell-based neutralization assay. Complementarity-determining regions (CDRs) of 8D3 were further grafted onto the stable framework of the huFv 4D5 to improve thermostability. The resulting hybrid antibody 9NT/S has superior stabilization and affinities beyond its original antibody. Human fibrosarcoma cellbased assays and in vivo analyses in mice indicated that the anti-IL-17A antibody 9NT/S efficiently Chinese Pharmaceutical Association
Introduction
IL-17A is a proinflammatory cytokine produced by the Th17 subset of T-cells 1 . Th17 cells are an identified subset of T helper cells associated with chronic inflammation, autoimmune disorders, fibrotic disease, and cancer [1] [2] [3] [4] . Therefore, the development of IL-17Atargeted therapeutic agents has important clinical benefits 5 . Indeed, the anti-IL-17A antibodies secukinumab (AIN457), a human IgG1κ monoclonal antibody, and ixekizumab (LY2439821), a humanized IgG4 monoclonal antibody, have demonstrated significant effectiveness in treating these diseases, particularly psoriasis, psoriatic arthritis and ankylosing spondylitis 6, 7 . Secukinumab or Ixekizumab prevents IL-17A from binding to its receptor and inhibits its ability to trigger inflammatory responses, which play a key role in the development of various diseases. Several agents targeting the IL-17A are currently under clinical trials as well. The ongoing studies focus on the efficacy of anti-IL-17 antibodies (e.g., bimekizumab, ALX-0761, CJM112, CNTO 6785, and SCH-900117), nanoantibodies (e.g., MSB0010841) and dual anti-IL-17/TNF-α inhibitors (e.g., ABT-122, COVA322) 8, 9 . Thus, IL-17A is an attractive target for intervention 5, 10 .
Monoclonal antibodies (mAbs), which constitute the main class of biotherapeutics, have been recognized as major medical tools for the treatment of multiple diseases in recent decades [11] [12] [13] [14] . The success of antibody therapeutics has introduced competition in the development of novel therapeutic mAbs according to a first-inclass strategy for promising targets and a best-in-class strategy for clinically validated targets 15 . In vitro display technology, mAbs humanization, and human immunoglobulin transgenic mice have made it possible to obtain fully human mAbs 16 . Humanized antibodies or fully human antibodies not only have significantly reduced immunogenicity but also exhibit properties similar to those of human IgGs 17 . Display technology can rapidly separate specific mAbs with high affinities during optimization of the lead mAbs [18] [19] [20] . In the current study, we utilized several approaches to optimize anti-IL-17A antibodies with potential best-in-class candidates. We initially isolated a novel fully human monoclonal antibody to human IL-17A (Clone: 7H9) from a large naïve human phage-displayed scFv library. However, the modest neutralization potency limits its therapeutic applications. The current study presents our strategies to improve the binding affinity, stability and neutralization potency of 7H9. Both phage and yeast antibody displays are widely employed to increase antibody affinity in vitro 16, 21 . The advantages of yeast over phage display include the ability to directly measure equilibrium dissociation constant (K D ) on the yeast surface and enrich high-affinity clones by flow cytometry without expression, purification, and characterization for a large number of different clones 16 . Therefore, the variable regions of 7H9 were randomized by error-prone PCR and high affinity clones were selected by yeast-displayed technology. Following analyses of residue substitutions by back-mutations and alanine scanning, we found an affinity-matured clone (Clone: 8D3) but it has low thermostability. It has been reported that properties such as stability and expression vary among particular families of V-genes. V-genes from the VH1, VH3 and VH5 families are better bio-therapeutic candidates than those from other families 22 . To improve the properties of these unstable V-genes, through a technique known as CDR grafting, the antigen-binding loops of a donor framework are transferred to an acceptor framework with known favorable properties 23 . Interestingly, through the above approaches, we have developed a CDRgrafted thermostable clone (Clone: 9NT/S) that exhibits improved binding and neutralization activities against IL-17A in vitro and in vivo. This leading antibody might act as a promising best-inclass drug candidate for treating IL-17A-related diseases.
Materials and methods
2.1. Cells, media, and plasmids HT1080 cells were obtained from China National Infrastructure of Cell Line Resource (Beijing, China) and maintained at 37 1C, 5% CO 2 , in Gibco MEM media (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco), 2 mmol/L l-glutamine, 20 mmol/L HEPES buffer pH 7.3 and 1 Â penicillin-streptomycin (Gibco). 293ET cells were purchased from Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (Beijing, China). FreeStyle TM 293-F cells were obtained from Invitrogen (Carlsbad, CA, USA) and maintained as company instructions. Saccharomyces cerevisiae strains EBY100 (ATCC s MYA4941) was used for surface display. The vector pYD1(Addgene, Watertown, MA, USA) provided the backbone for all scFv surface-display experiments, while plasmid pFUSE-hIgG1-Fc2 (InvivoGen, San Diego, CA, USA) provided the backbone for scFv-Fc expression. The vector pFUSEss-CHIg-hG1, pFUSE2ss-CLIg-hk, and pFUSE2ss-CLIg-hL2 (InvivoGen) provided the backbone for human IgG1 expression. EBY100 was grown in YPD medium (10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose). SD-CAA (20 g/L dextrose, 6.7 g/L yeast nitrogenous base, 100 mmol/L sodium phosphate buffer pH 6.0 and 5.0 g/L bactocasamino acids lacking tryptophan and uracil) and SG-CAA (20 g/L galactose, 6.7 g/L yeast nitrogenous base, 100 mmol/L sodium phosphate buffer pH 6.0 and 5.0 g/L bacto-casamino acids lacking tryptophan and uracil) medium was used for pYD1-transformed EBY100 and protein induction. E. coli DH5α (Transgen Biotech, Beijing, China) was used for subcloning and preparation of plasmid DNA. E. coli XL1-Blue (Transgen Biotech) was used to rescue and amplify phage. XL1-Blue was grown in SB medium (30 g/L tryptone, 20 g/L yeast extract, 10 g/L MOPS, 10 g/mL tetracycline, pH at 7.4).
Library selection using phage display
Phage display construction and selection were conducted as previously described 16 . The library was grown overnight at 30 1C in SB medium supplemented with M13KO7 helper phage (NEB Ipswich, MA, USA), 100 mg/mL ampicillin, 50 mg/mL kanamycin and 10 mg/mL tetracycline. Phages were precipitated with a solution of PEG-8000 and NaCl to a concentration of 4% PEG-8000/3% NaCl followed by centrifugation at 12,000 rpm (Beckman Coulter, Brea, CA, USA). Phages were then resuspended in 1% (w/v) bovine serum albumin (BSA)/phosphate buffered saline (PBS). To select phages that bind to human IL-17A, recombinant phages were first pre-panned in an immunotube (Thermo Fisher Scientific, Waltham, MA, USA) coated with 4% (w/v) milk powder/PBS (pH 7.4), and subsequently transferred to another immunotube that had been coated with 2 mg/mL recombinant human IL-17A (PeproTech, Rocky Hill, NJ, USA) and blocked with 4% (w/v) milk powder/PBS (pH 7.4). Following a 2-h incubation, the tube was washed 5 times with PBS plus 0.1% Tween 20 (PBST) followed by 5 washes with PBS. Bound phages were then eluted by the addition of 1 mL glycine elution buffer (0.2 mol/L glycine-HCl, pH 2.2, 1 mg/mL BSA) for 10 min. The eluted phages were amplified by re-infection of E. coli XL1-blue, followed by three additional rounds of selection using 20 washes with PBST and 20 washes with PBS. Eluted phages from the fourth round of panning were used to re-infect E. coli XL1blue, single clones expanded in 96 deep well plates and treated with helper phage using previously described methods 24 . Culture supernatants containing phage were used in ELISAs with plates coated with recombinant IL-17A or BSA, followed by washing with PBST. Bound phages were detected using anti-M13 antibody conjugated to horse radish peroxidase (HRP) (GE Healthcare, Chicago, IL, USA) at a 1:5000 dilution in 4% milk powder in PBS, followed by detection with 3,3 0 ,5,5 0 -tetramethylbenzidine substrate. The reaction was stopped by the addition of 2 mol/L H 2 SO 4 and recorded at 450 nm using an Infinite M200 plate reader (Tecan, Männedorf, Switzerland). The positive clones were sequenced and analyzed in IMGT website for the heavy chain and light chain genes (http://www.imgt.org/IMGT_ vquest/vquest?livret ¼ 0&Option ¼ humanIg).
Protein expression in mammalian cells
IgGs were generated from scFv genes as described 25 . Briefly, VH genes were amplified using PCR and cloned into EcoRI-and NheIdigested pFUSEss-CHIg-hG1 vector. Similarly, VL genes were amplified, digested with EcoRI as well as BsiwI and cloned into pFUSE2ss-CLIg-hk. For V gene cloning, pFUSE2ss-CLIg-hL2 vector and PCR products were digested with EcoRI and AvrII.
Recombinant antibodies were produced in Freestyle TM 293-F cells (Life Technology, Carlsbad, CA, USA) following transient transfection with 1 mg/mL DNA at a DNA/PEI ratio of 1:2.5 (PEI, Polyscience) as previously described 25 . Antibodies were purified from culture supernatants using protein G-Sepharose (GE Healthcare) and dialyzed against PBS. Purified antibodies were loaded onto a Hiload 16/600 Superdex 200 gel filtration column (GE Healthcare) to remove aggregates, followed by analyses of the 'monomeric' antibodies using Superdex TM 200 Increase 3.2/300 (GE Healthcare). Purified proteins were concentrated to 4 mg/mL by a 10 kDa Centrifugal Filter Unit (Millipore, Burlington, MA, USA), filtered by 0.22 mm Millipore filter.
Affinity measurements using surface plasmon resonance
Binding assays were carried out using biolayer interferometry (BLI) by Octet RED96 system (ForteBio, Fremont, CA, USA). All steps were performed at room temperature in a 96-well plate containing 200 μL per well. Streptavidin-coated biosensors were loaded with 5 μg/mL biotinylated recombinant human IL-17A (Sino Biological, Beijing, China) for 300 s followed by washing. The sensors were then reacted for 300 s with 100 nmol/L antibodies and then moved to buffer containing wells for another 300 s. Kinetic parameters were analyzed and compared using ForteBio Data Analysis (ForteBio).
A Biacore T100 instrument (GE Healthcare) was used for all kinetics measurements. The affinity of IL-17A binding to anti-IL-17A antibody variants was determined by surface plasmon resonance (SPR) measurements on a Biacore T100 instrument (GE Healthcare). All samples were in HBST buffer (10 mmol/L HEPES with 0.15 mol/L NaCl, 3.4 mmol/L EDTA, and 0.005% Tween-20, pH 7.2). A CM5 Chip was air-initialized and activated with EDC/S-NHS. Each of the anti-IL-17A antibody variants was diluted in acetate buffer (pH 5.5) and immobilized onto the chip. After blocking available unbound sites on the chip with ethanolamine, the chip was washed with HBST buffer and rotated. IL-17A was run at 25 mL/min for 300 s at various concentrations, then followed by a 10-min dissociation step. Binding parameters were determined with the Langmuir single binding site model using BIAcore T100 evaluation 2.0.3. (GE Healthcare).
Construction of mutant scFv yeast display libraries
The yeast display vector pYD1 was modified to allow scFv library construction by sequential cloning of antibody heavy (VH) and light (VL) chain gene repertoires (Supporting Information Fig. S3 ). The resulting vector (pYDs) used the GS linker between the VH and VL genes which were flanked by restriction enzyme sites for cloning the V-genes. The V5-tag and His6-tag were at the Cterminal of scFv in pYDs. The modified gene fragment was synthesized and cloned into the pYD1 backbone for scFv library construction and affinity maturation.
The gene encoding the 7H9 scFv was randomized using a GeneMorph II random mutagenesis kit (Stratagene, San Diego, CA, USA) to give a high mutagenesis rate. Primers were designed to PCR-amplify the VH gene or VL gene (Supporting Information  Table S4 ) from pYDs-7H9 construct. After 5-7 rounds of error-prone PCR reactions, the mutated VH or VL scFv gene was gel-purified using gel extraction kit (Qiagen) and the resulting repertoire (10 μg) was cloned directly into Saccharomyces cerevisiae strain EBY100 by gap repair into 50 μg of digested pYDs, which created the 7H9 VH-Mut library or 7H9 VL-Mut library, respectively. Transformation mixes were subcultured in SDCAA. Library size was determined by plating serial dilutions of the transformation mixture on SDCAA plates. After subculturing, scFv display was induced by culturing in SGCAA medium for 48 h at room temperature. The VHVk-Mut library was also constructed by a similar approach. The VL mutant fragment was PCR-amplified and cloned directly into an AscI-and SaI-digested VH-Mut sub-library by gap repair.
Isolating candidate scFv clones using magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS)
An enrichment of the affinity-improved clones was performed as described previously 16 . Briefly, 2 Â 10 9 yeast cells were used for this step. Biotinylated recombinant human IL-17A (Sino Biological) and 200 μL of streptavidin microbeads (Miltenyi Biotec, San Diego, CA, USA) were used for MACS to isolate antigen-specific scFvs. The eluted cells were grown in SDCAA medium and then induced in SGCAA. Alternatively, anti-biotin microbeads (Miltenyi Biotec) were used during successive MACS selections to decrease the enrichment of clones that bound to the secondary reagent. After expansion, the MACS output cells were further enriched by FACS (BD Biosciences) using procedures and protocols similar to those described previously 16 . 2 Â 10 8 cells were washed and resuspended in FACS buffer (1% BSA in PBS) and incubated with biotinylated recombinant human IL-17A. After incubation, cells were washed and incubated in FITC conjugated anti-V5 (1:1000, Abcam, Cambridge, UK) and APC conjugated Streptavidin (1:1000, ThermoFisher Scientific) for 1 h at 4 1C. The labeled cells were washed and sorted. Typically, the highest 0.1%-0.3% of the IL17A-binding population was gated in the sorting. Collected cells were grown in SDCAA medium and used for the next round of sorting after induction in SGCAA as described above. After the final round of sorting, 96 individual clones were picked, induced, and incubated with biotinylated recombinant human IL-17A, as detected by FITC conjugated anti-V5 and APC conjugated Streptavidin to identify the best candidates.
Measurement of yeast-displayed scFv affinity for IL17A
Quantitative equilibrium binding was determined using yeast displayed scFv and flow cytometry as described previously 16 . In brief, seven concentrations from 200 nmol/L to 1.56 nmol/L of biotinylated recombinant human IL-17A were used. Incubation volumes and the number of yeast cells stained were chosen to keep the number of antigen molecules in 10-fold excess above the number of scFv. The scFv-displaying yeasts were detected by FITC conjugated anti-V5 and APC conjugated Streptavidin. Finally, the yeasts were washed by cold FACS buffer and the mean fluorescence intensity (MFl) of IL17A binding was measured by flow cytometry. The MFI was plotted against the concentration of antigen and the K D was determined by Eq. (1):
where y is MFl at a given antigen concentration, m0 is antigen concentration, m1 is MFI of the no antigen control, m2 is MFl at saturation, and m3 is K D . The equilibrium titration data were fit to a reversible binding model using Prism 5 Software (GraphPad Inc., San Diego, CA, USA) to determine the K D .
Generation and rapid characterization of scFv-Fc fusions
In general, two extra digest sites, KpnI and SalI, were inserted into pFUSE-hIgG1-Fc2 between EcoRI and BglII to facilitate the rapid constructs transfer. DNA of pDYs-scFv was digested with KpnI and SalI and ligated into the modified pFUSE-hIgG1-Fc2. Vectors were used to transiently transfect 293ET cells. On the next day of transfection, the culture medium was changed to protein-free medium (Invitrogen). On the fifth day after transfection, supernatant containing IgG was collected, serially diluted with protein-free medium and mixed with 10 nmol/L recombinant human IL-17A (Peprotech) at room temperature for 1 h. Then these mixtures were incubated with HT1080 cell at 37 1C in 5% CO 2 for 24 h as described above. Measurement of IL-6 in culture supernatants was performed using human IL-6 ELISA kit (eBioscience, San Diego, CA, USA) according to manufacturer's description.
Antibody affinity measurements by ammonium thiocyanate assay
Estimation of the antibody affinity was performed by chaotropic ELISA using increasing concentrations of ammonium thiocyanate from in PBS-T as previously described 26 . Briefly, a constant 100 ng on hIL-17A was coated onto plates overnight. After blocking, antibody incubating and washing, increasing concentrations of ammonium thiocyanate from 0 to 3.5 mol/L were added to the wells. After 10 to 15 min, the plates were washed and the remaining antibody was detected by ELISA.
2.10. ELISA assay for IL-17A binding 96-well Costar ELISA plates (Corning Inc., Corning, NY, USA) were coated with 100 μL of 1 μg/mL human IL-17A (PeproTech) in PBS over night at 4 1C. The plates were blocked for 2 h with blocking buffer (PBS containing 4% skimmed milk powder), followed by washing four times with PBS containing 0.1% Tween20. Next, titrated amounts of purified antibody variants diluted in blocking buffer were added to the plates and incubated for 1 h. Following washing, bound protein was detected using HRP conjugated goat-anti-human IgG antibodies (CWBIO, Cambridge, MA, USA) at a 1:8000 dilution in blocking buffer, followed by detection with 3,3 0 ,5,5 0 -tetramethylbenzidine substrate. The reaction was stopped by the addition of 2 mol/L H 2 SO 4 and recorded at 450 nm using a Tecan Infinite M200 plate reader.
Protein thermostability by ELISA
The purified antibodies were diluted in PBS with 1% BSA to a final concentration of 1 mg/mL. The variants were then incubated for 30 min at different temperatures ranging from 37 to 100 1C by a thermal cycler (Bio-Rad, Hercules, CA, USA). The reaction was terminated by flash freezing the proteins in liquid nitrogen. The proteins were held at -80 1C and then were tested the bindings to human IL-17A in ELISA. Determination of IC 50 values was calculated using Prism curve fitting software (GraphPad Inc.).
Protein thermostability by differential scanning calorimetry
Thermal unfolding profiles of anti-IL-17A antibody variants were measured by differential scanning calorimetry (DSC) using a VP-Capillary DSC system (GE Healthcare) 27 Two hours after injection, orbital venous sinus blood samples were collected. Sera were then separated and measured to determine the level of murine Gro-α with an ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
Statistical analysis
Data are shown as mean7standard error of the mean (SEM), unless otherwise indicated. Multiple groups comparisons were analyzed by one-way ANOVA followed by Duncan's test in Prism 5 (GraphPad Inc.). P o 0.05 was considered statistically significant.
Results

Isolation of antibodies to human IL-17A from a large naive phage-displayed scFv library
A large naive scFv antibody library was prepared and maintained as previously described by our laboratory 24 . The primary library has approximately 3.7 Â 10 8 transformants. After infecting Cre recombinase-expressing bacteria with the primary library, the light and heavy chain genes of the variable region (VL and VH) exchanged and their diversity exponentially increased 28 . The effective library sizes should be $1.7 Â 10 11 , and 80% of VH/VL DNAs have full length open reading frames without stop codons.
This phage-displayed scFv library was used for selection against recombinant human IL17A. After four rounds of panning, specific phages were enriched toward the antigen and monitored by phage ELISA. Phage scFvs that showed at least five-fold higher signals than the control values in the phage ELISA were preliminarily identified as positive clones (Fig. 1A) . These positive binders were sequenced and assigned according to the IMGT database (http://www.imgt.org). The sequence data revealed 45 completely different anti-IL-17A scFv clones (Supporting Information Table S1 ). We did not find any scFv clone with identical or similar CDRs sequences to those of clinical anti-IL-17A antibody AIN457 or LY2439821 (Supporting Information Fig. S1 ). The heavy chain VH1 (16/45, 35 .5%) and VH6 (20/45, 44 .4%) gene segments were found to be the most frequent among the analyzed human VH sequences, followed by the VH3 (9/45, 20%) gene family. Within the human V-gene light chain sequences, Vλ3 gene family (23/45) constituted 51.1% of all analyzed sequences, followed by Vκ1 (6/45, 13.3%), Vκ2 (2/45, 4.4%), Vκ3 (4/45, 8.9%), Vλ1 (6/45, 13.3%), and Vλ2 (4/45, 8.9%) (Fig. 1B) .
These results indicate that most of the dominant germline families were represented in the leads generated after panning.
To rapidly validate these distinct phage clones through in vitro neutralization assay, genes of scFv fragments were transferred from phagemids to a vector encoding an Fc-fusion cassette. The mammalian expression vector, pFUSE2-scFv-Fc allows the rapid transient expression of the scFv gene as scFv-Fc fusions. The cell culture supernatants of all 45 distinct scFv-Fc fusions were collected, serially diluted and pre-mixed with 10 nmol/L recombinant human IL-17A. The IL-17A-containing supernatants were then used to stimulate HT-1080 cells to produce IL-6 29 . The results showed that at least 12 scFv-Fc fusions (7A8, 7C12, 7A4, 7G11, 7B6, 7H9, 7A6, 7F4, 7G11, 7H8, 7F10 and 7F1) had potential neutralizing effects ( Fig. 1C and Supporting Information Fig. S2 ). To further narrow the range of the candidate antibody pool, the relative affinity of the antibody was measured by ammonium thiocyanate assays 30 . We found that 7A6, Table S2 , Fig. S2 and panel D. þ, increase; þþ, strong increase; -, no effect. (D) IL-6 inhibition curves of 7H9, 7G1 and AIN457 (CON) in IgG1 format. HT1080 cells were treated in triplicate with antibodies pre-mixed with 10 nmol/L IL-17A and IL-6 levels determined by ELISA. Data are shown as the mean 7 SD (n ¼ 3). IC 50 was calculated using GraphPad Prism 5.0. 7A8, 7H9, and 7G1 scFv-Fc fusions had relatively higher binding affinity than the others (Supporting Information Table S2 ).
These four scFvs, as well as AIN457, were then converted into IgG1 by cloning the scFv variable regions into vectors encoding human IgG1 HC and LC (κ or λ) vectors. Antibodies were purified and assessed by SDS-PAGE and HPLC (data not shown), and then serially diluted to measure their neutralization activity. The results show that 7H9 and 7G1 are able to mildly inhibit IL-6 production in HT1080 cells (Fig. 1D) , but 7A6 and 7A8 in IgG1 format have no blocking effect (Fig. 1C) . The calculated IC50 values of 7H9 (166 nmol/L) and 7G1 (1392 nmol/L) for IL-17A inhibition were higher than that of the reference antibody AIN457 (5.2 nmol/L). Furthermore, we analyzed the binding behaviors of 7H9 and AIN457 over recombinant human IL-17A by surface plasmon resonance 18 . The association rate constant (K on ) of 7H9 is $ 16-fold faster than that of the reference antibody AIN457, while the dissociation rate constant (K off ) is $400-fold faster than that of AIN457, resulting in the decreased K D binding behavior in general ( Table 3 ). K off is known to be an important parameter and have a significant correlation with neutralization measures 31, 32 . These results suggest that affinity to IL-17A is a major determinant of neutralization by 7H9, which indicates that performing affinity maturation, especially slower K off , might be a plausible way to improve neutralization.
Enrichment of high-affinity mAbs using yeast surface display
A YSD approach was employed to achieve affinity maturation. First, the 7H9 scFv gene was sub-cloned into the expression vector pYDs (Supporting Information Fig. S3 ) for YSD. To improve the contribution of VH or VL to affinity and neutralization, we separately mutated VH and VL in two different libraries. The 7H9 VH fragment gene was randomly mutated using error-prone PCR. The resulting repertoire was directly cloned into pYD1-7H9-scFv. This step resulted in a 7H9 VH-Mut (mutant) library containing 2.2 Â 10 6 transformants. A 7H9 VL-Mut library with 1.9 Â 10 6 transformants was generated using similar methods ( Fig. 2A) .
Two rounds of enrichment were carried out on magnetic bead columns 16, 32 . In the first round, we used 100 nmol/L biotinylated IL-17A and streptavidin-magnetic microbeads to capture the bound yeast. In the subsequent round of MACS, we used the same concentration of biotinylated IL-17A but altered the microbeads to anti-biotin magnetic microbeads. The output was subjected to one more round of sorting on FACS by gating the highest 0.1%-0.3% binders against 100 nmol/L biotin-IL-17A (Fig. 2B ). Following two rounds of MACS plus one round of FACS enrichment, the third mutation yeast library was constructed ( Fig. 2A) . The output of the 7H9 VH-Mut and 7H9 VL-Mut libraries generated after the first round of FACS enrichment provided mutants with abundant diversity and improved affinity (Fig. 2B) . The output plasmid pool was extracted from yeast and transfected into E. coli. Afterwards, the VL mutant fragments were PCR-amplified and cloned directly into the digested VH-Mut sub-library resulting in the VHVL-Mut library. This library was subjected to three rounds of FACS selection using decreasing concentrations of biotinylated IL-17A varying from 50 to 5 nmol/L (Fig. 2B ). From the output of the last round of FACS enrichment, we identified nine more distinct clones, which showed the higher biotinylated IL-17A-binding values in monoclonal screening (Fig. 3A) . The K D improvement of each affinity-matured clone was measured by flow cytometry with the purified biotinylated IL-17A compared with the original clone 7H9. The data show that the K D s of all the affinity-matured clones were higher than that of 7H9 (Fig. 3B) . The best clone, 8D3, showed a 10.3-fold increase in binding (Fig. 3C) .
For functional characterization, we converted these scFvs to full-length IgG1 format. The K D s for each IgG were determined using surface plasmon resonance. Compared with 7H9, the clone 8D3 displayed $16-fold improvement in K off , with a total $30fold improvement in K D by Octet Fortebio (Table 1) , while $233fold in K off with a total $8-fold in K D by Biacore ( Table 3 ). The neutralization of 8D3 has a 15-fold improvement over 7H9 (Table 1 ). However, 8D3 showed worse thermostability measured by DSC with a Fab melting temperature (T m ) value of 59.4 1C than that of its original clone 7H9 with a T m value of 66.8 1C (Table 3 ). These results suggest that 8D3 has low thermostability, though it has been affinity-matured.
Identification of the critical residues for antigen-antibody interaction
The residues which were mutated and selected through yeastdisplayed random mutagenesis contributed to antibody affinity maturation. Three residues (L30G, L70S and L92aV) were evolved in 8D3 light chain, and six residues (H15P, H35D, H65N, H83S, H93V and H97D) in 8D3 heavy chain compared to those in 7H9 (Fig. 4) . To assess which residues play the key role, we individually mutated them back to their original residues. We found five back-mutations (L70 S-T , L92a V-D , H15 P-S , H35 D-N and H83 S-T ) that had no or low effects on the antibody affinity measured with an ammonium thiocyanate assay. However, four mutants (L30 G-S , H65 N-S , H93 V-A and H97 D-E ) significantly lost their antigen bindings (Supporting Information Table S3 ). These results show that L30G in CDRL1, H65N in CDRH2, and H97D in CDRH3 are responsible for the improvement of antibody affinity, consistent with that CDRs are the major relevant sites for antigen binding 33 . Moreover, if H94 alanine of 7H9 structurally close to or in CDRH3 region is replaced by valine, an aliphatic hydrophobic amino acid, which might affect the conformation of the binding loop and ameliorate the antigen binding.
To further investigate the critical residues for antigen-antibody interactions, alanine scanning mutagenesis was carried out in both CDRs of heavy and light chains 34 . Each CDR non-alanine residue in 8D3 was mutated to alanine by site-directed mutagenesis. The effects of these mutations were assessed through analyzing the binding activity of purified IgG1 proteins with an ammonium thiocyanate assay. Unexpectedly, one mutation (L53 D-A ) was able to enhance the binding ( Table 2 ). These results indicate that residues that have lost their bindings are functionally critical for antigen-antibody interactions ( Table 2) ; these results are also consistent with the previous analyses of back mutations. Four alanine substitutions (L30 G-A , H65 N-A, H93 V-A and H97 D-A ) are harmful to their interactions with antigen ( Table 2 ).
Thermostability improvement through CDR grafting
Given that the antibody 8D3 was not sufficiently stable, we improved its stability by grafting its binding residues onto the framework of the huFv 4D5 (simply denoted here by "4D5"). CDR grafts have primarily been introduced to reduce the immunogenicity of murine antibodies used in human in vivo applications. CDR grafting can also be used to improve the biophysical properties of antibodies by grafting their antigen specificities to a framework with better biophysical properties 23, 35, 36 . The CDRs are usually grafted onto the 4D5-framework, leading to a significant improvement of both expression yield and thermodynamic stability 36, 37 . The 4D5 framework consists of a VH that is essentially identical to the germline IGHV 3-66 (IMGT nomenclature) 38 and the Vκ derived from germ-line IGKV 1-39 (IMGT nomenclature) 38 , while the 8D3 framework is the same as its parent clone 7H9 framework, which is derived from the germ-lines IGHV 6-1(IMGT nomenclature) and germ-IGLV3-19 (IMGT nomenclature) (Supporting Information Table S1) 38 . It has been reported that antibodies with the HV 6 framework show poorly stability and expression 22 . Based on these conditions, we built a homology model of 8D3 and compared it to . CDR residues are colored in red. Sequences were aligned by using the Clustal Omega program. Residue labels and CDR definitions are according to Kabat (1987) . () indicates these residues were retained after CDR grafting onto the 4D5 framework. the X-ray structure of the human 4D5 version 8 Fv fragment (PDB entry 1fvc) (Fig. 5A) 39 . In VH and VL domains, in addition to CDR residues, several residues in the 'outer loop' of VH and VL, which are sometimes referred to as CDR4, are usually considered in studies (residues H69, H71, H75-H77, and L66-L71). These "outer loops" maintain the conformation and play a role in antigen binding. For example, residue L66 is usually Gly in κ light chains and assumes a positive Φ angle. If this residue is replaced by a non-Gly residue (Arg in 4D5), the outer loop assumes a different conformation, bending away from the upper core domain 23, 36 .
In VH domains, substitutions of residue H6, H67 and H82 can have a drastic effect on stability and potentially on antigen affinity as these residues determine the conformation of the framework 36 (Fig. 5B) . In Vκ domains, residue L4 of the N-terminus (Leu in 8D3 and 7H9) packs together with certain residues of CDR-L1, CDR-L2, the outer loop, and CDR-L3 to form the upper core domain 23 (Fig. 5C ). Additionally, certain residues (H24I, H37I, H48L, and H93V), which are in proximity to CDR regions, were retained to support their CDR structures (Fig. 5B) . The necessity of H93V has been confirmed as described above, and it cannot be replaced. To further optimize the affinity, the mutation (L53 D-A ) was also included (Fig. 5C ). To determine the extent to which the "outer loop" of the light chain affects the functionality of a loop graft, 9C53A CDRs are on the hybrid 4D5 framework with the 4D5 "outer loop" of the light chain, while clones 9NT or 9NS with the 7H9 or 8D3 light chain "outer loop". In addition, the homology models of 8D3 and 9NT were aligned and analyzed in PyMOL (Fig. 5D ). This was done by looking at the structural similarity of 8D3 versus 9NT, particularly in the CDR regions. Thus, the 8D3 CDRs were grafted on the 4D5-framework through total gene synthesis and a series of mutants were generated (Fig. 4) .
To characterize these mutants, 9C53A, 9NS and 9NT were converted into full-length IgG1. They showed no detectable aggregation and degradation (Fig. 6A ). Compared with their parent clone 8D3, 9C53A exhibited slight improvement in K D but great increase in the Fab T m value from 59.4 to 76.3 1C by DSC ( Fig. 6B , C, and Table 3 ). 9NT and 9NS showed high affinity (2.81 Â 10 -10 mol/L for 9NT, 2.91 Â 10 -10 mol/L for 9NS). 9NS and 9NT displayed $ 1.7-fold improvements in K off relative to that of 8D3 (Table 3 , and Supporting Information Fig. S4 ). The Fab T m values of both 9NS (76.7 1C) and 9NT (77.4 1C) were close to that of 9C53A (76.3 1C) and $18 1C higher than that of 8D3 (59.4 1C) by DSC. Furthermore, their stabilities were measured with AIN457 through thermal gradients. In this assay, full-length IgG1 9NS and 9NT showed 5 1C higher thermal tolerance than AIN457 (Fig. 6C ). Generally, 9NS and 9NT behave similarly in affinity and thermostability assays. These results suggest that "outer loops" maintain the antibody conformation and CDR grafting benefits the affinity and thermostability of antibodies.
Cell-based assay and in vivo analysis of optimized anti-IL-17A antibodies
To investigate the neutralizing ability of the anti-IL-17A antibodies, antibodies were tested in a neutralization assay. The results showed that both 9NS and 9NT were able to inhibit IL-6 production in a similar manner as the reference antibody AIN457 in HT1080 cells. The calculated IC 50 values of 9NS (10.5 nmol/L) and 9NT (9.2 nmol/L) for IL-17A inhibition were slightly better than that of AIN457 (15.6 nmol/L) ( Fig. 7A) .
Generally, approximately 20 ng/mL 9NS or 9NT was sufficient to inhibit 10 nmol/L IL-17A-induced IL-6 secretion in HT1080 (Fig. 7A ). Here, 9NS and 9NT function similarly and are viewed as the same clone (simply denoted here by "9NT/S"). Because 9NT specifically bound to human IL-17A without cross-reaction with other IL-17 family cytokines or mouse IL-17A (Supporting Information Fig. S5 ), recombinant human IL-17A was employed in the following experiments. To further examine the in vivo inhibitory activity of anti-IL-17A antibodies, we conducted animal experiments by measuring the IL-17A-induced Gro-α secretion in mouse sera 40 . We found a 9-fold increase in Gro-α levels in mouse sera collected 2 h after human IL-17A injection (1.5 mg/kg). 9NT IgG1 antibody (2 mg/kg) reduced the Gro-α level in mouse sera from 1574 7 117 pg/mL to 650 7 130 pg/mL, exhibiting a similar efficiency to that of the AIN457 antibody (Fig. 7B) . Thus, the optimized antibody 9NT/S showed strong neutralization in vitro and in vivo.
Discussion
Phage display technology represents one of the most powerful tools for the production and selection of recombinant, fully human antibodies 18 . The advantages of phage-display antibody technology include a completely in vitro antibody selection process without mouse immunization, the rapid discovery of leading mAb candidates, less dependence on the complexity of antigens than other techniques, and a high throughput approach for screening mAbs 18 . Antibodies, especially those derived from IgM libraries, usually have low affinity for clinical applications 41 .
To overcome this limitation, we need to perform affinity maturation to increase affinity, activity and bioactivity. In this study, we employed a strategy for parallelly mutating the VH and VL chains of the 7H9 scFv separately and subsequently combining optimized mutants. For this purpose, three different yeast libraries were generated and screened against antigens with decreasing concentrations using an equilibrium method. Although combining the affinity-improved VH and VL mutants might not produce binders with higher affinity as previously reported 42 , the beneficial mutations in VH and VL mutants have a synergistic binding effect and thus ultimately result in increased affinity in most cases 32 . From the VHVL-Mut library, several affinity-improved clones were isolated. Compared with the original clone 7H9, the affinity-matured clone 8D3 showed an $ 233-fold increase in K off , with an overall $8-fold improvement in K D by Biacore. Furthermore, after analysis of these mutated residues, we found that three residues-L30G, H65N and H97D-in the CDR loops were predicted to be directly involved in antigen binding. In addition to antigen-binding regions, one mutation with a clear contribution to the affinity improvements, H93V, immediately follows the cysteine before the CDRH3 region and is sometimes used to identify the N-terminal residues on the CDRH3, which can affect loop conformation 43 . In this study, using the in vitro affinity maturation method, we improved the affinity of 7H9 and obtained the clone 8D3 with a slower off-rate, K off . However, the Fab melting temperature (T m ) of 8D3 decreased to 59.4 1C, which is 7.4 1C lower than that of the original antibody 7H9 by DSC. Several approaches have been reported to improve the thermalstability of antibodies 44 : in vitro evolution by grafting antigenbinding loops onto a framework with more favorable biophysical properties 23, 35, 36 , combining random mutagenesis at elevated temperature 45 , implementing consensus-based designs 46 , disulfide bond engineering 47 and computational modeling 48 . Because the biophysical properties can be transferred between VH6 and VH3 formats 49 , and because of the unstable nature of VH6/Vλ3, we used the CDR grafting approach to transfer the binding sites of 8D3 to the artificial human consensus framework of 4D5 to improve its properties in a straightforward manner. In this study, a structural model of 8D3 was generated by homology modeling. Compared to the structure of 4D5 (1PDB entry 1fvc), certain residues adjacent to the CDRs, as well as residues that may determine the conformation of the "outer loops" of upper core domains, were retained to preserve the topology of the potential antigen interaction surface. Moreover, residues L4, H6, H67 and H82, which are located inside the hybrid 4D5 framework, are critical for maintaining the framework structure. Structurally, these residues are buried directly underneath the CDRs or outer loops, inaccessible to protein antigens and are therefore not expected to affect immunogenicity. Our strategy proved to be successful. Incorporation of affinity-matured CDRs into the stabilized scaffold resulted in a highly stable, high-affinity antibody clone 9NT/S with a 1.7-fold higher K D and an $17 1C higher Fab T m than clone 8D3. The results are consistent with a previous report that mutations designed to stabilize antibodies can also lead to concomitant gains in affinity 45 .
In the current study, all mature clones with improved affinity and thermostability exhibited enhanced neutralization potency against human IL-17A. In the neutralization assay, 8D3 displayed an $ 15-fold improvement in IC 50 over 7H9, while 9NT and 9NS behaved similarly. However, we did not compare the IC 50 values of these variants at the same time, and thus obtained different IC 50 values for the reference AIN457. Relatively, 8D3 displayed an $ 2-fold higher IC 50 than AIN457, while 9NT/S had an $1.5-fold lower IC 50 than AIN457. In addition, the in vivo inhibitory activity of 9NT was as potent as that of AIN457. Thus, 9NT/S was the best clone with superior affinity, thermostability and neutralization activity after rounds of optimization.
IL-17 is a proinflammatory cytokine involved in the progression of autoimmune diseases, such as rheumatoid arthritis and psoriasis, fibrotic diseases, chronic obstructive pulmonary diseases, and cancer, among others 1 . Targeting IL-17A offers an attractive treatment option for these diseases. Here, we implemented evolutionary approaches in vitro to discover and improve the biophysical properties of the fully human anti-IL-17A antibody 7H9. The affinity-matured and thermostability-improved antibody 9NT/S characterized in this study is a potential best-in-class candidate, either alone or in combination with other human inflammatory inhibitors, for IL-17A-related autoimmune diseases and cancer.
Conclusions
Antibodies are important tools for a broad range of applications because of their high specificity and ability to recognize target molecules. However, only a subset of antibodies possesses biophysical properties ideally suited for therapeutic or diagnostic antibodies. There is great demand for antibodies exhibiting affinity, stability, expression yield, resistance to aggregation and long half-life 22 . In the current study, we describe a novel fully human antibody against human IL-17A with high affinity, thermal stability and neutralization potency in vitro and in vivo. Specifically, we isolated a fully human antibody (7H9) with poor dissociation rate constant and thermostability from a large naïve phage-displayed scFv library. To improve its neutralization activity, we affinity-matured 7H9 through yeast-displayed random mutagenesis libraries. Moreover, the thermostability of this antibody was optimized through CDR grafting. As a result, the antibody 9NT/S against IL-17A might achieve superior therapeutic efficacy with a lower dose relative to AIN457. These approaches also have broad implications for the engineering of antibodies isolated from phage-displayed libraries.
